AURORA, Colo., Jan. 27, 2026 — Navidence, a technology company focused on defining health data and supporting researchers in study design, today announced it has completed its Series Seed preferred funding round, co-led by Grand Ventures (Grand Rapids, Michigan) and Nina Capital (Barcelona, Spain).

The life sciences industry is increasingly embracing ethically obtained health data, or real-world data (RWD), but determining which RWD is appropriate for specific research use cases, such as clinical trials, remains hampered by tedious, manual processes that burden research teams.

Founded in 2022, Navidence offers AI-native technology and professional services that make it radically easier to design and deploy clinical research studies using RWD. The company’s platform develops Computable Operational Definitions (CODefs)—standardized, human and computer readable definitions of key study elements—creating a bridge between clinical healthcare and research while providing the consistency, precision, efficiency, and trust demanded by regulatory agencies.

“There’s an enormous opportunity to make real-world data more usable and trustworthy,” said Aaron Kamauu, CEO and co-founder of Navidence. “With this funding, we’re advancing tools that directly reduce burdens on research teams, making the work—from protocol creation to study execution—more efficient and quickly aligning stakeholders throughout the process.”

RWD plays an increasingly significant role in how therapies are developed, evaluated, and used, but researchers often struggle with fragmented and inconsistent definitions—the basic building blocks of data science. Navidence’s approach combines technology, curated CODef libraries, and expert services so teams can more confidently design studies, agnostically and objectively selecting fit-for-purpose RWD.

“As real-world data becomes increasingly central to drug development and regulatory decision-making, the industry needs more than access to data—it needs clarity, consistency, and trust in how that data is defined and used,” said James Hill, Partner at Grand Ventures. “Navidence is building foundational infrastructure that helps life sciences teams translate complex, fragmented healthcare data into standardized, computable definitions that can be reused and trusted across studies. Their combination of software and thought-leading domain expertise is deeply embedded in customer workflows, and we believe it positions Navidence to become core infrastructure for RWD-driven research.”

“At Nina Capital, we back companies that solve fundamental bottlenecks in healthcare through meaningful innovation,” said Sebastian Anastassiou, Partner and Head of Investments at Nina Capital. “Navidence is providing the essential ‘Rosetta Stone’ for real-world data, transforming disparate health information into standardized, computable evidence. By bridging the gap between clinical care and rigorous research, they aren’t just improving study design—they’re building the infrastructure necessary to make RWD-driven research a global standard.”

About Grand Ventures

Grand Ventures is an early-stage venture capital firm that invests in high-growth companies across sectors including digital health, Fintech, and DevOps. The firm partners with founding teams in the U.S. and beyond to help them scale category-defining technologies.

About Nina Capital

Nina Capital is a European venture capital firm based in Barcelona that invests in early-stage health technology companies at the intersection of data, computing, and life sciences. The firm backs founders around the world building technology-enabled solutions to address critical healthcare needs, deploying pre-seed and seed capital to fuel their growth.

About Navidence

Navidence is a technology company that helps healthcare and life sciences organizations design and assess the use of real-world data in clinical research studies and clinical trials. Through its platform and Computable Operational Definitions (CODefs), Navidence enables consistent, transparent, and reproducible analysis of complex real-world data to support smarter research and better patient outcomes.

For media inquiries, please contact:

Andrew Ecob
Chief Commercial Officer
Navidence, Inc.
+1 (833) 991- 0344
[email protected]
navidence.com

SOURCE Navidence, Inc.

Funding supports continued platform expansion and AI-powered diligence innovation as private markets become core to advisory portfolios

ATLANTA, Jan. 27, 2026 — Gridline, a turnkey alternatives management platform designed to help advisory firms build and manage private market investments, today announced it has raised $18.5 million in Series A funding led by FINTOP.

The funding will accelerate Gridline’s mission to replace fragmented systems and manual workflows with a single, integrated platform purpose-built to support private market investing with the scale, reliability, and operational rigor required in the wealth channel.

Private market investments have evolved from niche allocations to a core component of client portfolios. Yet many advisory firms continue to manage these investments across disconnected tools, spreadsheets, and service providers, creating operational risk, limited scale, and slowed adoption. In a 2025 CFA Institute Global Survey of investment professionals, transparency in valuation reporting and performance measurement ranked among the top concerns about private markets. With private market assets projected to reach $32 trillion by 2030, the need for scalable, purpose-built infrastructure is accelerating.

“There’s no shortage of tools in this space, but most solve only a narrow slice of the problem,” said Logan Henderson, co-founder and chief executive officer of Gridline. “We built Gridline as an end-to-end platform advisors can rely on to run private market programs with confidence and consistency. By owning the underlying data infrastructure, we keep information standardized, up-to-date, and actionable, so firms have accurate insights in one place, exactly when they need them. That foundation delivers the intelligence, control, and reliability advisors have been missing in private markets.”

Gridline provides advisory firms with a centralized platform that supports the full private markets operating lifecycle, replacing spreadsheets, PDFs, and disconnected portals with a single system for investment diligence, onboarding, execution, oversight, and reporting. This foundation helps firms reduce manual effort, mitigate operational risk, and scale private market offerings with institutional discipline.

“It’s surprising no one had fixed how painful it was to manage investor relationships and fund operations, especially with efficiency being so important to clients,” said Larry Cummings, partner at GENCapital Advisory Partners. “Gridline filled the gap everyone else danced around. Now I can focus on strategy and portfolio design, not chasing documents or cleaning up reporting.”

Based on customer feedback, advisory firms using Gridline report up to a 90% reduction in time spent on manual reconciliation, along with an estimated 10–30 hours saved per investment on diligence-related work and monitoring.

“Across wealth management and private banking, firms are constantly challenged to deliver best-in-class private market solutions at scale. Yet there had not been a platform purpose-built to facilitate these workflows with the control and consistency required until Gridline,” said Rick Kushel Managing Partner at FINTOP. “Gridline is solving a foundational problem for the 22 trillion dollar industry and we’re excited to support their next phase of growth.”

The new funding will support continued innovation across the Gridline platform, beginning with AltComply, the company’s AI-powered diligence capability. AltComply automates document ingestion, standardizes analysis, and surfaces key risks to help firms evaluate private investments more efficiently and consistently. The company will also expand its team across engineering, go-to-market, operations, and fund administration.

About Gridline
Gridline is a turnkey, end-to-end platform purpose-built for private market investing in the wealth channel. The company works with registered investment advisers (RIAs), multi-family offices, and private banks to help them manage and scale private market investment programs with institutional rigor. By rebuilding private markets infrastructure from the ground up on a ledger-native foundation, Gridline replaces fragmented tools and manual workflows with a single, integrated platform spanning diligence, execution, administration, and reporting. The result is greater consistency, transparency, and control, making it easier for advisory firms to scale alternatives as a core part of their business. For more information, visit gridline.co.

About FINTOP
FINTOP = Financial Technology Operating Partners. FINTOP backs the builders’ rewiring finance. With offices in Nashville & New York, the venture firm has $700 MM+ in committed capital across five funds and a team with decades of industry experience as entrepreneurs, operators, & investors. More via fintopcapital.com

Media Contact
AJ Traver-Williams
Head of Marketing, Gridline
[email protected]

SOURCE Gridline

Advanced biosynthesis company will accelerate commercialization of critical pharmaceutical ingredients and establish U.S. manufacturing operations

MENLO PARK, Calif., Jan. 27, 2026 — Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has completed a second close of its Series C financing, raising an additional $24 million. Combined with additional available capital and non-dilutive funding, including multiple project agreements with the U.S. government, the company has secured more than $175 million over the past year.

Proceeds from the financing will be used to expand Antheia’s commercial manufacturing capacity, advance the company’s vast pipeline of late-stage biosynthetic pharmaceutical ingredients to market, and establish its U.S. manufacturing operations to support national onshoring priorities.

“Advanced biosynthesis has immense potential to transform pharmaceutical supply chains and unlock a new era of innovative medicines,” said Dr. Christina Smolke, CEO and co-founder of Antheia. “Building on the success of our Series C, this additional infusion of capital will fuel our efforts to address urgent supply chain vulnerabilities and more broadly, lead a paradigm shift for pharmaceutical manufacturing.”

The second close was led by ATHOS KG and America’s Frontier Fund, with participation from several existing investors, including Global Health Investment Corporation (GHIC), who co-led the initial Series C close with EDBI.

“America’s Frontier Fund invests in companies that strengthen U.S. industrial leadership and secure critical supply chains,” said Jeff Karras, General Partner at America’s Frontier Fund. “Antheia is redefining how essential medicines are made by combining advanced biosynthesis with scalable domestic manufacturing. This approach addresses longstanding shortages, long lead times, and geopolitical risk. We are excited to support Antheia as it builds a more resilient and secure U.S. pharmaceutical ecosystem.”

Today’s news follows several major milestones spanning 2024 and 2025, including Antheia’s first commercial delivery of thebaine — the key ingredient used to produce Narcan — and two U.S. government project agreements to onshore pharmaceutical supply chains. In November 2025, Antheia also announced a strategic partnership with TAPI to further commercialize its pipeline.

About Antheia
Antheia is the advanced biosynthesis company transforming pharmaceutical manufacturing and innovation for the 21st century. Antheia’s commercially proven technology platform produces high-value pharmaceutical ingredients in a fraction of the time compared to legacy approaches while significantly reducing supply chain risk. The company provides its global pharmaceutical customers with a resilient, efficient supply of critical ingredients at scale, while expanding the innovation frontier for new therapeutic development. Backed by leading investors and recognized by the U.S. government as a priority technology for public health and national and economic security, Antheia is manufacturing the medicines the world needs today while enabling tomorrow’s breakthrough therapeutics. For more information, visit www.antheia.bio.

MEDIA CONTACT:
Mission North for Antheia
[email protected]

SOURCE Antheia

SINGAPORE, Jan. 27, 2026 — EPG recently completed its Series B financing, raising nearly US$100 million. The round was co-led by international investment firms Forebright and Silicon Peak, with participation from GL Ventures, NRL Capital, YF Capital, and Rockets Capital. In 2025, EPG also completed its Series A and A+ rounds, raising tens of millions of U.S. dollars from investors including Eastern Bell VC, laying a solid foundation for its next phase of growth.

Founded in 2004 by a team with over two decades of industry experience, EPG is a modular data center solution provider specializing in factory-prefabricated integration of power, IT, and cooling systems. Proceeds from the Series B financing will support capacity expansion, working capital, and global growth, strengthening EPG’s ability to deliver large-scale, high-power-density AI data centers globally.

The global data center industry is facing growing efficiency challenges, particularly in overseas markets such as Southeast Asia and Europe, where weak local supply chains and shortages of skilled labor lead to long construction cycles and higher costs. At the same time, AI-driven workloads are increasing requirements for delivery speed, power density, and thermal efficiency, pushing traditional construction models to their limits.

Against this backdrop, EPG addresses these challenges through modular, factory-prefabricated data center solutions. Its MDC approach shifts the majority of construction activities to the factory, where modules are assembled and tested before rapid on-site installation and commissioning. Backed by manufacturing hubs in Johor Bahru and Shanghai, end-to-end global delivery teams, and in-house technologies such as cold-plate liquid cooling systems achieving PUE below 1.3 and self-developed diesel generator sets, EPG enables faster, more reliable, and cost-efficient data center deployment across international markets.

Alick Wan, Founder, Chairman and CEO of EPG, said: “This Series B financing reflects strong confidence from leading global investors. Looking ahead, we will continue to invest in R&D, manufacturing, and global delivery capabilities to support fast, reliable data center deployment for customers worldwide.”

For more information, visit www.epg-module.com or contact [email protected]. 

About EPG

EPG is a Singapore-headquartered provider of modular and prefabricated data center infrastructure, powered by dual R&D centers in Singapore and Shanghai and advanced manufacturing hubs in Malaysia and China. With over 20 years of engineering expertise, EPG delivers innovative and sustainable solutions for hyperscale, cloud, and enterprise deployments across APAC, EMEA, the Americas, and other global markets.

SOURCE EPG Singapore Pte Ltd

Funding will scale hospital deployments for groundbreaking CT:VQ™ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more

LOS ANGELES and MELBOURNE, Australia, Jan. 26, 2026 — 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ™” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.

CT:VQ™ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ™. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”

What the funding enables for hospitals and health systems

4DMedical will use the funding to expand U.S. availability of CT:VQ™ and support health systems with implementation at scale, including:

• Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ™ into existing clinical workflows and drive consistent utilization
• Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base.

Built to integrate into clinical workflows

4DMedical’s products are delivered through a Software-as-a-Service (SaaS) model designed to integrate with existing hospital infrastructure. The company also highlighted strategic partnerships, including with Philips, aimed at supporting broader adoption pathways.

Availability

Hospitals and imaging networks interested in evaluating CT:VQ™ can contact 4DMedical for implementation information, workflow considerations, and a demonstration.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that creates and deploys the most advanced software-based cardiothoracic imaging technology—integrating both proprietary algorithms and artificial intelligence. 4DMedical’s software platform delivers deep, quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease with significantly greater precision.

These insights help pulmonologists, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and surgical planning. 4DMedical’s solutions are designed to integrate into existing clinical workflows. They provide actionable, patient-specific information that supports better decision-making and operational efficiency across a range of respiratory conditions. Learn more at www.4dmedical.com.

SOURCE 4DMedical

Powerhouse Ventures leads investment in CVector’s novel AI solution for energy intensive industries.

NEW YORK, Jan. 26, 2026 — CVector announces an oversubscribed $5 million USD seed round led by Powerhouse Ventures, with participation by Fusion Fund, Hitachi Ventures, Myriad Venture Partners, and Schematic Ventures. CVector will use the funds to accelerate hiring in sales and product development and assist customers in scaling their current deployments.

Founded in November 2024 by industry veterans from Shell and CERN, CVector is already deployed across public utilities, advanced manufacturing, and chemical production. Its customers include ATEK Metals, known for operational excellence in complex metals processing as well as chemical companies like Ammobia, which is reinventing centuries old production processes.

“CVector’s AI native solution provides real time recommendations in the context of dynamic feedstocks, operating metrics, and customer demand,” says Richard Zhang, co-founder and CEO. “CVector sharpens decision-making around optimal production, ensuring every action is grounded in improved economics.”

Using high-resolution supply chain, control system, and market data, CVector generates prioritized recommendations based on economic models tailored to each facility’s operating parameters, evaluating every option by its impact on profitability.

“Contextualized industrial data may be the fuel for AI, but CVector is the only solution which addresses the additional issues of economic optimization and accessibility by end users,” says Emily Kirsch, Founder and Managing Partner of Powerhouse Ventures. “Addressing all three issues is required in the new generation of AI industrial software for improved decision making in production environments.”

CVector learns from operator behavior, tailoring recommendations based on how teams actually work. The result is faster root-cause analysis, smarter troubleshooting, and proactive system planning—all grounded in long-term historical trends and physical system understanding. These types of hybrid solutions augment human operators and engineers with AI-powered recommendations that are precisely targeted to drive measurable operational and economic improvements.

About CVector
CVector’s AI solution empowers industrial companies with real-time recommendations to optimize margins in the context of dynamic feedstock, energy, and finished product prices. Based on high resolution control systems and market data, these prioritized recommendations are built on economic models that account for the operating parameters of the facility, and analyze possible courses of action against their impact on profitability. CVector was founded in 2024 by industry veterans with expertise in AI and industrial software, and it is headquartered in New York City, USA.
For more information, visit www.cvector.com.

About Powerhouse Ventures
Powerhouse Ventures is a venture capital firm based in Oakland, California, investing in seed-stage startups that are building innovative software to rapidly decarbonize global energy and mobility systems. Founded in 2011, Powerhouse Ventures partners with entrepreneurs developing solutions for energy, mobility and industry.
For more information, visit https://powerhouse-ventures.co/.

About Fusion Fund
Founded in 2015, Fusion Fund is a Palo Alto–based venture capital firm that backs early-stage startups leveraging technical or data advantages. The firm partners with founders who have deep expertise in healthcare, enterprise AI, and industrial technology, helping them build the next generation of industry-defining companies. Fusion Fund invests in Pre-Seed, Seed, and Series A companies across the United States and Canada, with a focus on transformational businesses that address critical challenges in digitalization, efficiency, and scalability.
For more information, visit www.fusionfund.com.

About Hitachi Ventures
Hitachi Ventures is the global corporate venture capital arm of Hitachi, Ltd. With more than $1 billion in assets under management, Hitachi Ventures partners with ambitious founders to build world-changing innovations. The firm invests in four core themes driving the future of our planet: intelligent infrastructure, sustainable industry, life sciences, and digital ecosystems. By blending the global power of Hitachi with the speed of innovation, Hitachi Ventures acts as a force multiplier for startups transforming the world around us.
For more information, visit www.hitachi-ventures.com.

About Myriad Venture Partners
Myriad Venture Partners is an early-stage venture firm defining the future of business solutions. Investing in visionary AI, B2B software, and industrial transformation leaders, Myriad brings decades of expertise and a robust corporate and financial partnership network. By connecting entrepreneurs, corporate partners, industry leaders, and co-investors, Myriad is changing the ways businesses operate, compete, and create value. The firm is based in New York with portfolio companies across North America and Europe.
For more information, visit www.myriadventures.com.

About Schematic Ventures
Schematic Ventures is a venture capital firm focused on early-stage investments in supply chain, manufacturing, and industrial technologies. Schematic partners with technical founders building the next generation of operational infrastructure.
For more information, visit www.schematicventures.com.

Media Contact:
Richard Zhang
202-579-9478
[email protected]

SOURCE CVector

One of the largest first-time funds of its kind as well as the largest dedicated private equity GP-led secondary platform in North America. Fundraise significantly exceeds its $1.5 billion target and marks a major expansion into single-asset continuation fund investing.

LOS ANGELES, Jan. 26, 2026 — Leonard Green & Partners, L.P. (“LGP”) announced today the final closing of Sage Equity Investors and its related entities (“Sage I”), its inaugural investment program dedicated to investing primarily in single-asset continuation funds sponsored by third-party private equity managers.

Sage I closed with over $3.6 billion of total commitments, significantly exceeding its initial target of $1.5 billion, including a meaningful commitment from LGP’s partners.

“Sage represents a natural extension of LGP’s long history of investing in high-quality businesses and partnering with exceptional sponsors and management teams,” said Jonathan Sokoloff, Managing Partner of LGP. “We believe the successful launch of Sage reflects both the strength of our platform and the compelling opportunity we see in this rapidly evolving segment of the private markets.”

Sage was established to capitalize on the continued growth of the continuation fund market, seeking to provide flexible, long-term capital solutions for high-quality assets while partnering with experienced sponsors and management teams.

“The single-asset continuation fund market continues to grow in its size, sophistication, and importance,” said David Fox, Co-Head of the Sage Fund. “Sage is purpose-built to provide speed, certainty and scale to leading sponsors, and we are excited about the depth of the potential opportunity set ahead.”

The Sage fundraise attracted a broad and diverse group of global investors including public and corporate pension plans, sovereign wealth funds, endowments, family offices, insurance companies, and other institutional investors, with strong support from both existing and new relationships to LGP.

“We are humbled by the trust our limited partners have placed in us,” said Garrett Hall, Co-Head of the Sage Fund. “Sage is designed to be a thoughtful, long-term partner to exceptional companies, and we believe our scale, discipline, and collaborative approach positions us well to support high-performing assets and sponsors and deliver outstanding returns to our limited partners.”

Kirkland & Ellis LLP served as legal counsel to LGP in connection with the formation of Sage Equity Investors.

About Leonard Green & Partners
LGP is a leading private equity investment firm founded in 1989 and based in Los Angeles with over $75 billion of assets under management. The firm partners with experienced management teams and often with founders to invest in market-leading companies. Since inception, LGP has completed over 160 investments in the form of traditional buyouts, going-private transactions, recapitalizations, growth equity, and selective public equity and debt positions. The firm primarily focuses on services, including consumer, healthcare, and business services, as well as distribution and industrials. For more information, please visit www.leonardgreen.com.  

SOURCE Leonard Green & Partners, L.P.

N.I.S. New Investment Solutions leads investment in the leading provider of solar steam

DUBAI, UAE, Jan. 26, 2026 — GlassPoint, the leader in solar industrial process heat, today announced it has closed a $20M funding round led by N.I.S. New Investment Solutions, a Liechtenstein-based asset management firm, with participation from returning investor MIG Capital. The investment will advance existing megaprojects with Searles Valley Minerals in California and Ma’aden in Saudi Arabia, as well as power expansion across the globe with a focus on projects in the U.S. Southwest, Southern Europe, the Middle East and South America.

More energy is used globally in the form of industrial process heat (26%) than all forms of electricity combined (20%), according to the International Energy Agency. Unlike electricity, industrial process heat is notoriously difficult to decarbonize, primarily due to the low cost of burning fossil fuels to generate heat.

More than 50% of industry is located in regions sunny enough to benefit from GlassPoint technology. In those locations, GlassPoint’s technology delivers superior economics for industrial process heat compared to burning fossil fuels or electrification.

“In many parts of the world, solar energy is now the lowest cost source of industrial power, creating an opportunity to simultaneously reduce operating costs and emissions,” said Takashi Sato, Founder of N.I.S. “GlassPoint is a proven solution for this moment and has already won the confidence of some of the most discerning industrial organizations in the world, from oil and gas leaders to mining titans.”

“GlassPoint provides industry leaders with a proven solution to deliver industrial process heat at the lowest cost,” said Rod MacGregor, Chief Executive Officer at GlassPoint. “With this latest round of financing, we will expand into several new global markets where GlassPoint’s technology delivers compelling value. We look forward to helping leaders across mining, oil & gas, and building materials achieve a significant cost advantage against their competitors.”

The funding comes on the heels of GlassPoint’s partnership with Searles Valley Minerals to deploy 750 MWth of GlassPoint’s advanced solar technology to reduce costs while beginning to decommission the last two coal-fired plants in California. The company continues to advance its flagship 1.5 GWth project with Ma’aden to decarbonize a bauxite refinery in Saudi Arabia and help the Kingdom meet aggressive sustainability goals. Additionally, GlassPoint’s 330 MWth deployment in Oman has been providing steam on a daily basis since 2017.

GlassPoint’s unmatched ability to deploy at scale is based on multiple industry-first technologies. 

• GlassPoint’s Enclosed Trough is the lowest-cost way to convert sunlight into industrial heat, delivering nearly 70% of the energy available in sunlight directly to the customer.
• GlassPoint’s Unify Storage System stores solar heat during the day and releases it at night, enabling an uninterrupted supply of clean thermal energy whenever it is needed.

With the new funding, GlassPoint is expanding its Technology Center in Stuttgart, Germany, with leading technologists and engineers. The company is also hiring business development, engineering, and finance talent in Dubai and the United States.

About GlassPoint
GlassPoint is the leader in solar industrial process heat, with its technology powering 60% of the world’s solar industrial steam capacity. With the only solar industrial process heat solution proven at scale, GlassPoint delivers superior unit economics compared to fossil fuels and electrification. GlassPoint is helping industrial organizations significantly lower costs while delivering a reliable source of carbon-free steam. The company builds, owns and operates large-scale solar steam facilities to reduce carbon emissions in hard-to-abate industries such as mining and metals, chemicals, construction materials, oil and gas, desalination and more. Learn more at glasspoint.com.

About MIG Capital
MIG Capital is one of the leading German VC investors. Through its MIG funds, MIG invests in young deep tech and life sciences companies in German-speaking Europe and beyond. To date, the company has invested over €770 million in approx. 60 start-ups. MIG portfolio companies develop innovations in areas including biopharmaceuticals, energy and environmental technologies, advanced computing, digitalization / IoT, medical technology, and digital health. The MIG investment portfolio currently consists of more than 30 companies.

MIG’s investment team is made up of a dedicated group of engineers, scientists, physicians and entrepreneurs who use analytical and creative processes to assess the risks and opportunities of business models and technologies. Their reputation, experience and network provide excellent access to companies, institutions and decision-makers to support the growth of their portfolio companies.

In recent years, MIG Capital has realized more than ten successful portfolio company sales, including Siltectra (to Infineon) and Hemovent (to MicroPort). It has placed several companies on the stock exchange including BRAIN, NFON, BioNTech, and Immatics.

For further information, please visit www.mig.ag, www.mig-fonds.de or LinkedIn.

SOURCE GlassPoint

Led by AVP, the round empowers enterprises to shift IP development and management in-house, cutting legal spend by 50% and filing patents in under 24 hours

SAN FRANCISCO, Jan. 26, 2026 — The company announced a $15 million Series A funding round led by AVP to scale its AI-native IP platform – the first solution that allows enterprises to take control of their full IP lifecycle. Existing investors Eniac Ventures, Amplo VC, and Scrum Ventures also participated in the round.

“The traditional IP law firm model is broken. In house IP teams are being asked to support faster innovation cycles without increasing costs, despite law firm fees for drafting and prosecution reaching record levels,” explained Alec Sorensen, CEO and Co-Founder of Tradespace. “Today, Tradespace is dismantling that model and will continue to innovate in the IP Law sector thanks to the support and confidence of the financial partners behind this Series A funding round.”

For decades, in-house IP leaders have been forced to make a difficult economic trade-off: file fewer patents to save money, or exhaust budgets on routine filings. Tradespace eliminates this compromise. By integrating AI directly into the R&D workflow, Tradespace streamlines patent development – from invention harvesting to application drafting – allowing in-house IP teams to operate with the speed of a tech company while maintaining legal rigor.

“The billable hour acts as a tax on innovation, forcing companies to decide which ideas to protect based on budget rather than merit,” said Sorensen. “Even when law firms have moved to fixed fees, companies have had to pay in other ways, whether in increased costs on the backend for prosecution or lower speed and quality. Our platform allows IP teams to recapture their budget and operate with the speed of a software company, not a law firm.”

While “copilot” tools exist to simply draft text faster, Tradespace operates as an end-to-end IP Management Platform. Its embedded AI workflows empower IP teams to harvest new innovations, search for prior art, draft patents, respond to office actions, and even run licensing campaigns, while keeping attorneys in the loop to produce work that rivals senior partners.

The results are immediate. Tradespace clients report:

• 50% reduction in outside counsel spend
• 40% increase in invention disclosures from R&D teams
• Time-to-file compressed from weeks to days

“In-house teams are tired of the administrative trap. They want to be strategic architects, not invoice approvers,” said Manish Agarwal, General Partner at AVP. “Tradespace is the first company to successfully close the gap between software and legal services, giving corporations ownership of the entire process. We believe this platform will become the standard operating system for the Global 2000.”

The platform currently manages over 440K patents for over 80 organizations, including Fortune 500 tech giants and 75% of top US research universities. The Series A follows Tradespace’s November 2025 acquisition of Paragon Patents, cementing Tradespace’s technical lead in Agentic workflows and AI-driven patent drafting.

About Tradespace
Tradespace is the first end-to-end IP Management Platform designed to replace the billable hour with AI automation. By combining a secure system of record with proprietary, attorney-grade drafting technology, Tradespace empowers in-house teams to take control of the IP lifecycle – from invention disclosure to filing – without relying on inefficient outside counsel. Trusted by top universities and Fortune 500s, Tradespace is defining the future of intellectual property. For more information, visit tradespace.io.

About AVP 
AVP is an independent global investment platform focused on high-growth technology companies, ranging from deep tech to tech-enabled, across Europe and North America. The firm manages more than €2.5 billion in assets across four strategies: venture, early growth, growth, and fund of funds. Its multi-stage platform combines global research with local execution to drive investment. Since its establishment in 2016, AVP has invested in more than 60 technology companies. Through its dedicated expansion team, AVP works closely with founders, offering the expertise, connections and resources needed to unlock growth opportunities, and create lasting value through meaningful collaborations.

Contact:
Andrea Christman
Poston Communications
202.302.1511
[email protected]

SOURCE Tradespace